Assessing commercial opportunities for autologous and allogeneic cell-based products
Assessing commercial opportunities for autologous and allogeneic cell-based products
复制标题
DOI：
10.2217/rme.12.40
复制
发表时间：
2012-09-01
影响因子：
2.7
通讯作者：
Smith, Devyn M.
中科院分区：
文献类型：
--
作者：
Smith, Devyn M.
用于生产基于细胞的疗法的两种主要细胞来源是自体（自身衍生）和同种异体（来自供体）。本分析试图对这两种方法进行比较和对比，以了解市场上是否存在新的偏好。虽然目前正在进行的临床试验稍微偏向于自体方法，但很明显，这两种基于细胞的方法都在积极推行。该分析还详细分析了每种基于细胞的方法的商业优势，比较了每种方法的商品成本和理想指示类型。虽然同种异体疗法比自体疗法具有相当大的优势，但它们在潜在的免疫原性方面确实有明显的缺点。混合自体商业模式的引入使基于自体的疗法能够减轻基于同种异体细胞的疗法所享有的一些优势，包括商品成本。最后，两个案例研究表明，在单一疾病领域内，自体和同种异体细胞疗法都有足够的空间。
The two primary cell sources used to produce cell-based therapies are autologous (self-derived) and allogeneic (derived from a donor). This analysis attempts to compare and contrast the two approaches in order to understand whether there is an emerging preference in the market. While the current clinical trials underway are slightly biased to autologous approaches, it is clear that both cell-based approaches are being aggressively pursued. This analysis also breaks down the commercial advantages of each cell-based approach, comparing both cost of goods and the ideal indication type for each. While allogeneic therapies have considerable advantages over autologous therapies, they do have a distinct disadvantage regarding potential immunogenicity. The introduction of the hybrid autologous business model provides the ability for autologous-based therapies to mitigate some of the advantages that allogeneic cell-based therapies enjoy, including cost of goods. Finally, two case studies are presented that demonstrate that there is sufficient space for both autologous and allogeneic cell-based therapies within a single disease area.